cisplatin + docetaxel + nimotuzumab

Cisplatin + docetaxel + nimotuzumab is a combination regimen used primarily in the treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and has also been studied in advanced head and neck squamous cell carcinoma (HNSCC) and oral carcinoma. Cisplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis. Docetaxel is a taxane-class chemotherapeutic that stabilizes microtubules, inhibiting cell division. Nimotuzumab is a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking ligand binding and downstream signaling involved in tumor proliferation. This combination leverages cytotoxic chemotherapy with targeted anti-EGFR therapy to improve response rates and survival outcomes in patients with difficult-to-treat cancers[1][2][3].

Other names

cisplatin and docetaxel and nimotuzumabTPN regimen